Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Blood (2023) 142 (Supplement 1): 869.

https://doi.org/10.1182/blood-2023-187740

Published: 2023

Journal Articles

The Diversity of FLT3-ITD and the Prognostic Impact in Adult Acute Myeloid Leukemia

Jingyi Yang, Shanlan Mo, Xudong Wei, Xiaodong Lv, Baijun Fang, Yanli Zhang, Jian Zhou, Hu Zhou, Yuewen Fu, Quande Lin, Delong Liu, Yongping Song, Qianfei Wang, Keshu Zhou

Blood (2023) 142 (Supplement 1): 5756.

https://doi.org/10.1182/blood-2023-178989

Published: 2023

Journal Articles

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1

Chunrui Li, Lu-Gui Qiu, Di Wang, Yongping Song, He Huang, Jianyong Li, Bing Chen, Jing Liu, Yujun Dong, Kai Hu, Peng Liu, Xi Zhang, Jianqing Mi, Zhenyu Li, Kaiyang Ding, Shiyue Zhang, Guang Hu, Wen Wang

Blood (2023) 142 (Supplement 1): 761.

https://doi.org/10.1182/blood-2023-173427

Published: 2023

Journal Articles

Heritable SETBP1 Mutations Associated with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Jingyi Yang, Shanlan Mo, Xudong Wei, Xiaodong Lv, Ya Zhang, Yuewen Fu, Baijun Fang, Yanli Zhang, Jian Zhou, Hu Zhou, Quande Lin, Delong Liu, Yongping Song, Qianfei Wang, Keshu Zhou

Blood (2023) 142 (Supplement 1): 5684.

https://doi.org/10.1182/blood-2023-182788

Published: 2023

Journal Articles

Humanized Monoclonal Antibody IMM47, Targeting CD24, Exhibits Exceptional Anti-Tumor Efficacy By Blocking the CD24/Siglec-10 Interaction and Can be Used As Monotherapy or in Combination with Anti-PD1 Antibodies for Cancer Immunotherapy

Jifeng Yu, Song Li, Dianze Chen, Huiqin Guo, Yanan Yang, Dandan Liu, Chunmei Yang, Xing Bai, Wei Zhang, Li Zhang, Gui Zhao, Xiaoping Tu, Liang Peng, Sijin Liu, Yongping Song, Zhongxing Jiang, Ruliang Zhang, Wenzhi Tian

Blood (2023) 142 (Supplement 1): 7140.

https://doi.org/10.1182/blood-2023-172483

Published: 2023

Journal Articles

ZGGS15, a Novel IgG4 Bispecific Monoclonal Antibody Targeting Both LAG-3 and Tigit, Demonstrates Outstanding Anti-Tumor Activity and Can be Used As Monotherapy or in Combination with Anti-PD-1 Antibodies for Cancer Immunotherapy

Jifeng Yu, Tongcheng Dai, Hao Sun, Bin Zhang, Tyler Liban, Jessica Ochoa, Jackie Sheng, Yongping Song, Zhongxing Jiang, Zelin Sheng, Binhua Lv

Blood (2023) 142 (Supplement 1): 5764.

https://doi.org/10.1182/blood-2023-184775

Published: 2023

Journal Articles

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results

Blood (2023) 142 (Supplement 1): 3039.

https://doi.org/10.1182/blood-2023-181500

Published: 2023

Journal Articles

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Blood (2023) 141 (16): 1971–1981.

https://doi.org/10.1182/blood.2022017734

Published: 2023

Includes: Supplemental data

Journal Articles

Preliminary Safety and Efficacy Evaluation of IMM0306, a CD47 and CD20 Bispecific Monoclonal Antibody-Trap (mAb-Trap), from an Ongoing Phase I Dose-Escalation Study in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL)

Yuankai Shi, Yongping Song, Mingzhi Zhang, Hongmei Jing, Zhen Wang, Zhiming Li, Junyuan Qi, Fei Li, Wenyu Li, Jianliang Yang, Siman Gao, Huizi Ma, Heming He, Qiying Lu, Wenzhi Tian

Blood (2022) 140 (Supplement 1): 9323–9324.

https://doi.org/10.1182/blood-2022-157862

Published: 2022

Journal Articles

A Phase IV, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) As a Myeloablative Conditioning Regimen in Chinese Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Fengrong Wang, Zhen Cai, Dehui Zou, Wenming Chen, Yongping Song, Chengcheng Fu, Jiong Hu, Ting Yang, Xinchuan Chen, Jinsong Yan, Kaiyan Liu

Blood (2022) 140 (Supplement 1): 4845–4847.

https://doi.org/10.1182/blood-2022-163171

Published: 2022

Journal Articles

Novel Sirpα-Fc Fusion Protein IMM01 Exhibits Dual Anti-Tumor Activities By Targeting CD47/Sirpα Signal Pathway

Jifeng Yu, Song Li, Dianze Chen, Dandan Liu, Huiqin Guo, Chunmei Yang, Wei Zhang, Li Zhang, Gui Zhao, Xiaoping Tu, Liang Peng, Sijin Liu, Xing Bai, Yongping Song, Zhongxing Jiang, Ruliang Zhang, Wenzhi Tian

Blood (2022) 140 (Supplement 1): 3067–3068.

https://doi.org/10.1182/blood-2022-155977

Published: 2022

Journal Articles

Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7435–7436.

https://doi.org/10.1182/blood-2022-166465

Published: 2022

Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Blood (2022) 140 (Supplement 1): 203–204.

https://doi.org/10.1182/blood-2022-170698

Published: 2022

Journal Articles

Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patients

Blood (2021) 138 (Supplement 1): 46.

https://doi.org/10.1182/blood-2021-149350

Published: 2021

Journal Articles

Whole Genome Sequencing As an Unbiased and Simplified Approach to Molecular Karyotyping in AML/MDS

Xiaodong Lv, Tao Li, Dandan Zhu, Mengna Zhang, Yuexin CHENG, Zhenling Li, Yan Chen, Shiyong Li, Yinyin Chang, Mao Mao, Zunmin Zhu, Yongping Song

Blood (2021) 138 (Supplement 1): 4462.

https://doi.org/10.1182/blood-2021-144752

Published: 2021

Journal Articles

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 547.

https://doi.org/10.1182/blood-2021-152576

Published: 2021

Journal Articles

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Long Term Results of Phase II Study

Blood (2021) 138 (Supplement 1): 2638.

https://doi.org/10.1182/blood-2021-146491

Published: 2021

Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I -Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)

Blood (2021) 138 (Supplement 1): 3598.

https://doi.org/10.1182/blood-2021-153937

Published: 2021

Journal Articles

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs)

Mingyuan Sun, Junyuan Qi, Zi Chen, Hongli Zhang, Yongping Song, Aizong Shen, Huilan Liu, Jianying Huang, Fuling Zhou, Jie Jin, Ming Lu, Mohammad Ahmad, Lichuang Men, Wan Cen, Dajun Yang, Jianxiang Wang, Yifan Zhai

Blood (2021) 138 (Supplement 1): 3730.

https://doi.org/10.1182/blood-2021-152235

Published: 2021

Journal Articles

The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Lenalidomide in Chinese Patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma: Results of a Multicenter, Single-Arm, Phase 1b/2 Trial

Yuankai Shi, Yan Qin, Yongping Song, Keshu Zhou, Hui Zhou, Hongmei Jing, Ying Xiang, Zhao Wang, Zhen Wang, Aimin Zang, Ou Bai, Zhenyu Li, Huilai Zhang

Blood (2021) 138 (Supplement 1): 1351.

https://doi.org/10.1182/blood-2021-146440

Published: 2021

NARROW

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

The Diversity of FLT3-ITD and the Prognostic Impact in Adult Acute Myeloid Leukemia

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1

Heritable SETBP1 Mutations Associated with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Humanized Monoclonal Antibody IMM47, Targeting CD24, Exhibits Exceptional Anti-Tumor Efficacy By Blocking the CD24/Siglec-10 Interaction and Can be Used As Monotherapy or in Combination with Anti-PD1 Antibodies for Cancer Immunotherapy

ZGGS15, a Novel IgG4 Bispecific Monoclonal Antibody Targeting Both LAG-3 and Tigit, Demonstrates Outstanding Anti-Tumor Activity and Can be Used As Monotherapy or in Combination with Anti-PD-1 Antibodies for Cancer Immunotherapy

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Preliminary Safety and Efficacy Evaluation of IMM0306, a CD47 and CD20 Bispecific Monoclonal Antibody-Trap (mAb-Trap), from an Ongoing Phase I Dose-Escalation Study in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL)

A Phase IV, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) As a Myeloablative Conditioning Regimen in Chinese Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Novel Sirpα-Fc Fusion Protein IMM01 Exhibits Dual Anti-Tumor Activities By Targeting CD47/Sirpα Signal Pathway

Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patients

Whole Genome Sequencing As an Unbiased and Simplified Approach to Molecular Karyotyping in AML/MDS

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Long Term Results of Phase II Study

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I -Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs)

The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Lenalidomide in Chinese Patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma: Results of a Multicenter, Single-Arm, Phase 1b/2 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only